Chemical name | Trade name in the United States | Vendor | Ligand class | Net charge | Tissue distribution | Biliary excretion |
Group I: Associated with highest number of cases of nephrogenic systemic fibrosis | ||||||
Gadodiamide | Omniscan | GE Healthcare | Linear | Nonionic | Extracellular | None |
Gadopentetate dimeglumine | Magnevist | Bayer HealthCare Pharmaceuticals | Linear | Ionic | Extracellular | None |
Gadoversetamide | OptiMARK | Covidien | Linear | Nonionic | Extracellular | None |
Group II: Associated with few or no unconfounded cases* of nephrogenic systemic fibrosis | ||||||
Gadobenate dimeglumine | MultiHance | Bracco Diagnostics | Linear | Ionic | Extracellular | 3% |
Gadobutrol | Gadavist¶ | Bayer HealthCare Pharmaceuticals | Macrocyclic | Nonionic | Extracellular | None |
Gadoterate meglumine | Dotarem | Guerbet | Macrocyclic | Ionic | Extracellular | None |
Gadoteridol | Prohance | Bracco Diagnostics | Macrocyclic | Nonionic | Extracellular | None |
Group III: Limited number of administrations with no cases of nephrogenic systemic fibrosis | ||||||
Gadofosveset trisodiumΔ | Ablavar | Lantheus Medical Imaging | Linear | Ionic | Blood pool | None |
Gadoxetate disodium | Eovist | Bayer HealthCare Pharmaceuticals | Linear | Ionic | Hepatocellular | 50% |
* Unconfounded cases are those in which the implicated gadolinium agent was the only type that the patient received.
¶ Gadavist is also known as Gadovist in Europe.
Δ Gadofosveset trisodium, a group III GBCA, is no longer available for clinical use.Adapted from: American College of Radiology. ACR manual on contrast media, version 10.3, 2018. Available at: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf (Accessed on April 10, 2018).
Additional references:Do you want to add Medilib to your home screen?